AQST Aquestive Therapeutics Inc.

6.69
+0.03  (+1%)
Previous Close 6.66
Open 6.67
Price To Book 7.12
Market Cap 166967975
Shares 24,942,185
Volume 21,005
Short Ratio
Av. Daily Volume 119,770

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due January 2019.
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
NDA filing due early 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
CRL issued January 30, 2019 through partner Sunovion (private company).
APL-130277
Parkinson’s Disease with motor fluctuations

Latest News

  1. Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019
  2. Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
  3. Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation
  4. Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
  5. Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen
  6. Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer
  7. Aquestive Therapeutics, Inc.’s (NASDAQ:AQST) Shift From Loss To Profit
  8. Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters
  9. Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018
  10. Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  11. Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
  12. Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability
  13. The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates
  14. Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film
  15. Aquestive Therapeutics: 3Q Earnings Snapshot
  16. Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
  17. Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film
  18. Aquestive Therapeutics to Present at the Stifel 2018 Healthcare Conference
  19. Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19607553
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19597759
  3. 8-K - Current report 181244758
  4. 8-K - Current report 181227755
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163429
  6. 8-K - Current report 181163364
  7. 8-K - Current report 181146939
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181052633
  9. 8-K - Current report 181051227
  10. 8-K - Current report 181022430